Targeting Staphylococcus aureus in Pediatric Surviving Sepsis Bundles—Reply

Brendan J. McMullan, Asha C. Bowen, Steven Y C Tong

Research output: Contribution to journalLetterResearchpeer-review

Abstract

In Reply: We thank Schlapbach and MacLaren for their letter and comments on our article.1Staphylococcus aureus infections are the most common cause for admission to a pediatric intensive care unit for treatment of sepsis.2 We agree that vancomycin use as a risk factor for mortality in our study1 might in fact represent severity of disease rather than a problem with the antibiotic as such. We also agree that robust treatment protocols for S aureus–associated sepsis are urgently required. However, the evidence base to inform such protocols is sorely lacking. Important questions about the epidemiology and clinical treatment of staphylococcal bacteremia and sepsis remain, including optimal choice and duration of antibiotic therapy, benefit from combination therapy or antitoxin therapy, timing of intravenous to oral stepdown, and the role of further investigations such as echocardiography in children.
Original languageEnglish
Pages (from-to)301-302
Number of pages2
JournalJAMA Pediatrics
Volume171
Issue number3
DOIs
Publication statusPublished - Mar 2017

Fingerprint

Staphylococcus aureus
Sepsis
Pediatrics
Anti-Bacterial Agents
Antitoxins
Therapeutics
Pediatric Intensive Care Units
Vancomycin
Clinical Protocols
Bacteremia
Echocardiography
Epidemiology
Mortality
Infection

Cite this

McMullan, Brendan J. ; Bowen, Asha C. ; Tong, Steven Y C. / Targeting Staphylococcus aureus in Pediatric Surviving Sepsis Bundles—Reply. In: JAMA Pediatrics. 2017 ; Vol. 171, No. 3. pp. 301-302.
@article{83a87614e8e64da1985ef089d6e28b7a,
title = "Targeting Staphylococcus aureus in Pediatric Surviving Sepsis Bundles—Reply",
abstract = "In Reply: We thank Schlapbach and MacLaren for their letter and comments on our article.1Staphylococcus aureus infections are the most common cause for admission to a pediatric intensive care unit for treatment of sepsis.2 We agree that vancomycin use as a risk factor for mortality in our study1 might in fact represent severity of disease rather than a problem with the antibiotic as such. We also agree that robust treatment protocols for S aureus–associated sepsis are urgently required. However, the evidence base to inform such protocols is sorely lacking. Important questions about the epidemiology and clinical treatment of staphylococcal bacteremia and sepsis remain, including optimal choice and duration of antibiotic therapy, benefit from combination therapy or antitoxin therapy, timing of intravenous to oral stepdown, and the role of further investigations such as echocardiography in children.",
author = "McMullan, {Brendan J.} and Bowen, {Asha C.} and Tong, {Steven Y C}",
year = "2017",
month = "3",
doi = "10.1001/jamapediatrics.2016.4689",
language = "English",
volume = "171",
pages = "301--302",
journal = "JAMA Pediatrics",
issn = "1072-4710",
publisher = "American Medical Association",
number = "3",

}

Targeting Staphylococcus aureus in Pediatric Surviving Sepsis Bundles—Reply. / McMullan, Brendan J.; Bowen, Asha C.; Tong, Steven Y C.

In: JAMA Pediatrics, Vol. 171, No. 3, 03.2017, p. 301-302.

Research output: Contribution to journalLetterResearchpeer-review

TY - JOUR

T1 - Targeting Staphylococcus aureus in Pediatric Surviving Sepsis Bundles—Reply

AU - McMullan, Brendan J.

AU - Bowen, Asha C.

AU - Tong, Steven Y C

PY - 2017/3

Y1 - 2017/3

N2 - In Reply: We thank Schlapbach and MacLaren for their letter and comments on our article.1Staphylococcus aureus infections are the most common cause for admission to a pediatric intensive care unit for treatment of sepsis.2 We agree that vancomycin use as a risk factor for mortality in our study1 might in fact represent severity of disease rather than a problem with the antibiotic as such. We also agree that robust treatment protocols for S aureus–associated sepsis are urgently required. However, the evidence base to inform such protocols is sorely lacking. Important questions about the epidemiology and clinical treatment of staphylococcal bacteremia and sepsis remain, including optimal choice and duration of antibiotic therapy, benefit from combination therapy or antitoxin therapy, timing of intravenous to oral stepdown, and the role of further investigations such as echocardiography in children.

AB - In Reply: We thank Schlapbach and MacLaren for their letter and comments on our article.1Staphylococcus aureus infections are the most common cause for admission to a pediatric intensive care unit for treatment of sepsis.2 We agree that vancomycin use as a risk factor for mortality in our study1 might in fact represent severity of disease rather than a problem with the antibiotic as such. We also agree that robust treatment protocols for S aureus–associated sepsis are urgently required. However, the evidence base to inform such protocols is sorely lacking. Important questions about the epidemiology and clinical treatment of staphylococcal bacteremia and sepsis remain, including optimal choice and duration of antibiotic therapy, benefit from combination therapy or antitoxin therapy, timing of intravenous to oral stepdown, and the role of further investigations such as echocardiography in children.

UR - http://www.scopus.com/inward/record.url?scp=85015160536&partnerID=8YFLogxK

U2 - 10.1001/jamapediatrics.2016.4689

DO - 10.1001/jamapediatrics.2016.4689

M3 - Letter

VL - 171

SP - 301

EP - 302

JO - JAMA Pediatrics

JF - JAMA Pediatrics

SN - 1072-4710

IS - 3

ER -